Quale ruolo per i barbiturici nell'anno 2000

Translated title of the contribution: What is the future for barbiturates in XXI century?

G. G. Coppola, G. Gobbi

Research output: Contribution to journalArticle

Abstract

Phenobarbital is the oldest antiepileptic agent. It is an inexpensive antiepileptic drug with favourable pharmacokinetics and availability for oral and intravenous use and a relatively broad-spectrum, and it continues to be useful in the treatment of generalised tonic and tonic-clonic seizures and in partial seizures, especially with secondary generalisation. Its efficacy has been also demonstrated in the control of neonatal seizures and convulsive status epilepticus. The more potential adverse effects consist of the tendency to cause sedation, behaviour disturbances, developmental cognitive functions impairment, especially in infancy and childhood. Even though these effects seem to be overestimated and probably be due to excessive doses or too rapid increase in doses, they usually keep phenobarbital from being the antiepileptic drug of choice in many cases. Actually, at the present phenobarbital promotes less interest in studying its efficacy, mechanism of action and metabolism than the other antiepileptic drugs do, so that it risks to be removed from the use not because of its side effects but because its advantages are not sufficiently promoted.

Original languageItalian
Pages (from-to)349-355
Number of pages7
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number106-107
Publication statusPublished - 1999

Fingerprint

Barbiturates
Anticonvulsants
Phenobarbital
Seizures
Status Epilepticus
Cognition
Pharmacokinetics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Coppola, G. G., & Gobbi, G. (1999). Quale ruolo per i barbiturici nell'anno 2000. Bollettino - Lega Italiana contro l'Epilessia, (106-107), 349-355.

Quale ruolo per i barbiturici nell'anno 2000. / Coppola, G. G.; Gobbi, G.

In: Bollettino - Lega Italiana contro l'Epilessia, No. 106-107, 1999, p. 349-355.

Research output: Contribution to journalArticle

Coppola, GG & Gobbi, G 1999, 'Quale ruolo per i barbiturici nell'anno 2000', Bollettino - Lega Italiana contro l'Epilessia, no. 106-107, pp. 349-355.
Coppola, G. G. ; Gobbi, G. / Quale ruolo per i barbiturici nell'anno 2000. In: Bollettino - Lega Italiana contro l'Epilessia. 1999 ; No. 106-107. pp. 349-355.
@article{9af79104fad6416491555aebd227c67f,
title = "Quale ruolo per i barbiturici nell'anno 2000",
abstract = "Phenobarbital is the oldest antiepileptic agent. It is an inexpensive antiepileptic drug with favourable pharmacokinetics and availability for oral and intravenous use and a relatively broad-spectrum, and it continues to be useful in the treatment of generalised tonic and tonic-clonic seizures and in partial seizures, especially with secondary generalisation. Its efficacy has been also demonstrated in the control of neonatal seizures and convulsive status epilepticus. The more potential adverse effects consist of the tendency to cause sedation, behaviour disturbances, developmental cognitive functions impairment, especially in infancy and childhood. Even though these effects seem to be overestimated and probably be due to excessive doses or too rapid increase in doses, they usually keep phenobarbital from being the antiepileptic drug of choice in many cases. Actually, at the present phenobarbital promotes less interest in studying its efficacy, mechanism of action and metabolism than the other antiepileptic drugs do, so that it risks to be removed from the use not because of its side effects but because its advantages are not sufficiently promoted.",
keywords = "Indications for use, Phenobarbital, Side effects",
author = "Coppola, {G. G.} and G. Gobbi",
year = "1999",
language = "Italian",
pages = "349--355",
journal = "Bollettino - Lega Italiana contro l'Epilessia",
issn = "0394-560X",
publisher = "Lega Italiana contro l'Epilessia",
number = "106-107",

}

TY - JOUR

T1 - Quale ruolo per i barbiturici nell'anno 2000

AU - Coppola, G. G.

AU - Gobbi, G.

PY - 1999

Y1 - 1999

N2 - Phenobarbital is the oldest antiepileptic agent. It is an inexpensive antiepileptic drug with favourable pharmacokinetics and availability for oral and intravenous use and a relatively broad-spectrum, and it continues to be useful in the treatment of generalised tonic and tonic-clonic seizures and in partial seizures, especially with secondary generalisation. Its efficacy has been also demonstrated in the control of neonatal seizures and convulsive status epilepticus. The more potential adverse effects consist of the tendency to cause sedation, behaviour disturbances, developmental cognitive functions impairment, especially in infancy and childhood. Even though these effects seem to be overestimated and probably be due to excessive doses or too rapid increase in doses, they usually keep phenobarbital from being the antiepileptic drug of choice in many cases. Actually, at the present phenobarbital promotes less interest in studying its efficacy, mechanism of action and metabolism than the other antiepileptic drugs do, so that it risks to be removed from the use not because of its side effects but because its advantages are not sufficiently promoted.

AB - Phenobarbital is the oldest antiepileptic agent. It is an inexpensive antiepileptic drug with favourable pharmacokinetics and availability for oral and intravenous use and a relatively broad-spectrum, and it continues to be useful in the treatment of generalised tonic and tonic-clonic seizures and in partial seizures, especially with secondary generalisation. Its efficacy has been also demonstrated in the control of neonatal seizures and convulsive status epilepticus. The more potential adverse effects consist of the tendency to cause sedation, behaviour disturbances, developmental cognitive functions impairment, especially in infancy and childhood. Even though these effects seem to be overestimated and probably be due to excessive doses or too rapid increase in doses, they usually keep phenobarbital from being the antiepileptic drug of choice in many cases. Actually, at the present phenobarbital promotes less interest in studying its efficacy, mechanism of action and metabolism than the other antiepileptic drugs do, so that it risks to be removed from the use not because of its side effects but because its advantages are not sufficiently promoted.

KW - Indications for use

KW - Phenobarbital

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=0033493148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033493148&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0033493148

SP - 349

EP - 355

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 106-107

ER -